Analysis of clinical characteristics of 30 cases with systemic anaplastic large cell lymphoma

( views:241, downloads:0 )
Author:
WANG Lie-yang(Department of Hematology, Shanxi Cancer Hospital, Taiyuan 030013, China)
ZHAO Zhi-qiang(Department of Hematology, Shanxi Cancer Hospital, Taiyuan 030013, China)
LUO Yan-hong()
SU Li-ping(Department of Hematology, Shanxi Cancer Hospital, Taiyuan 030013, China)
ZHENG Yu-ping(Department of Hematology, Shanxi Cancer Hospital, Taiyuan 030013, China)
LI He-xin()
Journal Title:
JOURNAL OF LEUKEMIA & LYMPHOMA
Issue:
Volume 20, Issue 08, 2011
DOI:
10.3760/cma.j.issn.1009-9921.2011.08.008
Key Word:
Lymphoma, anaplastic large cell;Anaplastic mphomakinase;Prognosis

Abstract: Objective To study clinical characteristics and prognostic factors in systemic anaplastic large cell lymphoma (S-ALCL). Methods Clinical date of 30 systemic ALCL patients from Department Hemotology of Shanxi Cancer Hospital from December 1998 to September 2009 were reviewed. Results The median age of the 30 patients was 36 years old. The male/female ratio was 1.5:1.18 (60.0 %) 18/30 of the patients had B symptoms, 22 (73.3 %) had Ann Arbor stage Ⅲ-Ⅳ, and 18 (60.0 %) had extranodal disease at diagnosis. 14 (46.7 %) had elevated lactate dehydrogenase (LDH) level. The positive rate of ALK was 18 (60.0 %). Compared with ALK negative patients, ALK-positive patients were younger (u = 3.92, P=0.001).ALK expression and LDH level were important prognostic factors by Long-rank test. Conclusion S-ALCL usually occur in younger patients, with good response to chemotherapy and good prognosis. ALK negative and elevated LDH level are correlated to unfavorable prognosis. Combination chemotherapy is the major choice to these patients. High-dose chemotherapy maybe benefit to the patients who have adverse prognostic factors.

  • [1]Stein H,Mason DY,Gerdes J,et al.The expression of the Hogkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue:evidence that reed-sternberg cells and histiocytic malignancies are derived from activated lymphoid cells.Blood,1985,66:848-858.
  • [2]归薇,张巧花,王彤,等.25例间变性大细胞淋巴瘤的临床分析.中华血液学杂志,2007,28:694-695.
  • [3]Cheson BD,Homing SJ,Coiffier B,et al.Report on an international workshop to standardize reponse criteria for non-Hodgkin's lymphomas.NCI Sponsored International Working Group.J Clin Oncol,1999,17:1244-1253.
  • [4]杨艳丽,高子芬,周春菊,等.原发系统型间变性大细胞淋巴瘤56例临床特征和预后相关因素分析.白血病·淋巴瘤,2008,6:178-181.
  • [5]Falini B,Pileri S,Zinzanip L,et al.ALK+ lympboma:clinicopathological findings and outcome.Blood,1999,93:2697-2706.
  • [6]王凤华,李宇红,曾敬,等.57例原发系统型间变大细胞性淋巴瘤临床分析.癌症,2009,28:63-68.
  • [7]Mussolin L Pillon M,Amore ES,et al.Prevalence and clinical implications of bone marrow involvement in pediatric large cell lymphoma.Leukemia,2005,19:1643-1647.
  • [8]Medeiros LJ,Elenitoba-Johnson KS.Anaplastic large cell lymphoma.Am J Clin Pathol,2007,127:702-722.
  • [9]李金甘,李甘地,刘卫平,等.间变性大细胞淋巴瘤组织间变性淋巴瘤激酶及Survivin蛋白表达及其临床意义.中华病理学杂志,2006,35:213-217.
  • [10]Park SR,Baek JY,Kim DW,et al.Primary systemic anaplastic large cell lymphoma in a single Korean institution:clinical characteristics and treatment outcome.J Korean Med Sel,2006,21:633-638.
  • [11]Le Deley MC,Reiter A,Williams D,et al.Prognostic factors in childhood anaplastic large cell lymphoma:results of a large European intergroup study.Blood,2008,111:1560-1566.
  • [12]Muris JJ,Meijer CJ,Cillessen SA,et al.Prognostic significance of activated cytotoxic T-lymphocytes in primary nodal diffuse large B-cell lymphomas.Leukemia,2004,18:589-596.
  • [13]Suzuki R,Kagami Y,Takeuchi K,et al.Prognostic significance of CD56 expression for ALK positive and ALK negative anaplastic large cell lymphoma of T/null cell phenotype.Blood,2000,96:2993-3000.
  • [14]Kadin ME,Carpenter C.Systemic and primary cutaneous anaplastic large cell lymphoma.Semin Hematol,2003,40:244-256.
  • [15]Rosolen A,Pillon M,Garaventa A,et al.Anaplastic large cell lymphoma treated with a leukemia-like therapy:report of the Italian Association of Pediatric Hematollogy and Oncology (AIEOP)LNH-92protocol.Cancer,2005,104:2133-2140.
  • [16]Zhang M,Yao Z,Zhang Z,et al.Effective therapy for a murine model of human anap lastic large cell lymphoma with the anti-CD30monoclonal antibody,HeFi-1,does not require activating Fc receptors.Blood,2006,108:705-710.
  • [17]Wan W,Albom MS,Lu L,et al.Anap lastic lymphoma kinase activity is essential for the proliferation and survival of anaplastic large cell lymphoma cells.Blood,2006,107:1617-1623.
  • [18]Piva R,Chiarle R,Manazza AD,et al.Ablation of oncegenic ALK is a viable therapeutic approach for anaplastic large cell lymphomas.Blood,2006,107:689-697.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn